Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era | Zendy

Lawrence D. Lazar | Zendy; Mark J. Pletcher | Zendy; Pamela G. Coxson | Zendy; Kirsten BibbinsDomingo | Zendy; Lee Goldman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cost-Effectiveness of Statin Therapy for Primary Prevention in a Low-Cost Statin Era

Author(s) -

Lawrence D. Lazar,

Mark J. Pletcher,

Pamela G. Coxson,

Kirsten BibbinsDomingo,

Lee Goldman

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.110.986349

Subject(s) - medicine , statin , primary prevention , cost effectiveness , hydroxymethylglutaryl coa reductase inhibitors , secondary prevention , physical therapy , intensive care medicine , disease , risk analysis (engineering)

With wide availability of low-cost generics, primary prevention with statins has become less expensive. We projected the cost-effectiveness of expanded statin prescribing strategies using low-cost generics and identified conditions under which aggressive prescribing ceases to be cost-effective.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research